187
Anti-VEGF in the treatment of AMD
ascular membranes in age-related macular degeneration express
vascular endothelial growth factor. Invest Ophthalmol Vis Sci
1996; 37 (9): 1929-34.
30. Rudolf M, Winkler B, Aherrahou Z, Doehring L C, P Kacz-
marek, Schmidt-Erfurth U. Increased expression of vascular en-
dothelial growth factor associated with accumulation of lipids in
Bruch’s membrane of LDL receptor knockout mice. Br J Oph-
thalmol 2005; 89 (12): 1627–1630.
31. Boulton ME, Cai J, Grant MB. gamma-Secretase: a multifaceted
regulator of angiogenesis. J Cell Mol Med 2008; 12 (3): 781-95.
Epub 2008 Feb 8.
32. Ferrara N. Role of vascular endothelial growth factor in regu-
lation of physiological angiogenesis. Am J Physiol Cell Physiol
2001; 280 (6): C1358-66.
33. Chappelow AV, Kaiser PK. Neovascular age-related macular de-
generation: potential therapies. Drugs 2008; 68 (8): 1029-36.
34. Raig ET, Jones NB, Varker KA, Benniger K, Go MR, Biber JL,
Lesinski GB, Carson WE 3rd. VEGF secretion is inhibited by
interferon-alpha in several melanoma cell lines. J Interferon Cy-
tokine Res 2008; 28 (9): 553-61.
35. Michels S, Schmidt-Erfurth U, Rosenfeld PJ. Promising new
treatments for neovascular age-related macular degeneration. Ex-
pert Opin Investig Drugs 2006; 15 (7): 779-93.
36. Hayek S, Scherrer M, Barthelmes D, Fleischhauer JC, Kurz-Lev-
in MM, Menghini M, Helbig H, Sutter FK. First clinical experi-
ence with anecortave acetate (Retaane). Klin Monbl Augenheilkd
2007; 224 (4): 279-81.
37. Emerson MV, Lauer AK. Emerging therapies for the treatment of
neovascular age-related macular degeneration and diabetic macu-
lar edema. BioDrugs 2007; 21 (4): 245-57.
38. Emerson MV, Lauer AK Current and emerging therapies for the
treatment of age-related macular degeneration. Clin Ophthalmol
2008; 2 (2): 377-88.
39. Steinbrook R. The price of sight--ranibizumab, bevacizumab,
and the treatment of macular degeneration. N Engl J Med 2006;
355 (14): 1409-12.
40. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for
neovascular age-related macular degeneration. N Engl J Med.
2006;355:1419-1431. Abstract
41. Brown DM, Kaiser PK, Michels M, et al, for the Anchor Study
Group. Comparison of ranibizumab and verteporfin photody-
namic therapy for neovascular age-related macular degeneration.
N Engl J Med. 2006;355:1432-1444.
42. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Develop-
ment of ranibizumab, an anti-vascular endothelial growth factor
antigen binding fragment, as therapy for neovascular age-related
macular degeneration. Retina 2006; 26 (8): 859-70.
43. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ.
Pharmacokinetics of intravitreal ranibizumab (Lucentis). Oph-
thalmology 2007; 114 (12): 2179-82.
44. Rouvas AA, Papakostas TD, Vavvas D, Vergados I, Moschos
MM, Kotsolis A, Ladas ID. Intravitreal ranibizumab, intravit-
real ranibizumab with PDT, and intravitreal triamcinolone with
PDT for the treatment of retinal angiomatous proliferation: a
prospective study. Retina 2009; 29 (4): 536-44.
45. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III
clinical trial results. Ophthalmol Clin North Am 2006; 19 (3):
361-72.
46. Bressler NM, Chang TS, Fine JT, Dolan CM, Ward J; Anti-
VEGF Antibody for the Treatment of Predominantly Classic
Choroidal Neovascularization in Age-Related Macular Degen-
eration (ANCHOR) Research Group. Improved vision-related
function after ranibizumab vs photodynamic therapy: a rand-
omized clinical trial. Arch Ophthalmol 2009; 127 (1): 13-21.
47. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus
verteporfin for neovascular age-related macular degeneration. N
Engl J Med. 2006;355:1432-44.
48. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for
neovascular age-related macular degeneration. N Engl J Med.
2006;355:1419-31.
49. Kaiser PK, Blodi BA, Shapiro H, Acharya NR; MARINA Study
Group. Angiographic and optical coherence tomographic results
of the MARINA study of ranibizumab in neovascular age-related
macular degeneration. Ophthalmology 2007; 114 (10): 1868-
75.
50. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Sch-
neider S, Shams N. Randomized, double-masked, sham-con-
trolled trial of ranibizumab for neovascular age-related macular
degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145
(2): 239-248.
51. Holz FG, Korobelnik JF, Lanzetta P, Mitchell P, Schmidt-Erfurth
U, Wolf S, Markabi S, Schmidli H, Weichselberger A. The effects
of a flexible visual acuity-driven ranibizumab treatment regimen
in age-related macular degeneration: outcomes of a drug and dis-
ease model. Invest Ophthalmol Vis Sci 2010; 51 (1): 405-12.
52. Bolz M, Schmidt-Erfurth U. Ranibizumab EXCITE study:
Exploring the value of optical coherence tomography for the
management of ranibizumab therapy in age-related macular de-
generation. Presented at the 8th EURETINA Congress, Vienna,
Austria 22–25 May 2008.
53. Suñer IJ, Kokame GT, Yu E, Ward J, Dolan C, Bressler NM.
Responsiveness of NEI VFQ-25 to changes in visual acuity in
neovascular AMD: validation studies from two phase 3 clinical
trials. Invest Ophthalmol Vis Sci 2009; 50 (8): 3629-35.
54. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S,
Feuer W, Davis JL, Flynn HW Jr, Esquiabro M. A variable-dos-
ing regimen with intravitreal ranibizumab for neovascular age-
related macular degeneration: year 2 of the PrONTO Study. Am
J Ophthalmol 2009; 148 (1): 43-58.e1.
55. Dafer RM, Schneck M, Friberg TR, Jay WM. Intravitreal ranibi-
zumab and bevacizumab: a review of risk. Semin Ophthalmol
2007; 22 (3): 201-4.
56. NCT00331864. SUSTAIN: Study of Ranibizumab in Patients
with Subfoveal Choroidal Neovascularization Secondary to Age-
Related Macular Degeneration. Available at
-
trials.gov/ct2/show/NCT00331864 . Accessed January 18, 2010.
57. NICE Final Guidance. Ranibizumab and pegaptanib for age-
related macular degeneration. At
.
